Acinetobacter baumani
Reading File
Finding Sources
Searching PubMed
"Acinetobacter baumannii"[MeSH Terms] AND "drug resistance"[MeSH Terms]
Searching the Web
Acinetobacter baumannii 2025 treatment guidelines carbapenem-resistant
Reading File
Reading File
Reading File
Reading File
I now have comprehensive information. Let me compile the full answer.
Acinetobacter baumannii
Microbiology
Acinetobacter baumannii is a gram-negative, oxidase-negative, nonmotile, non-fermenting coccobacillus. The genus was first described in 1911 (as Micrococcus calcoaceticus) and renamed multiple times before settling on Acinetobacter by 1950. Key microbiologic features:
- Strictly aerobic
- Glucose-oxidizing (unlike A. lwoffii, A. haemolyticus)
- Phenotypic differentiation among Acinetobacter species is unreliable; MALDI-TOF MS or quantitative PCR are needed to confirm A. baumannii
- Gram stain: plump, paired gram-negative coccobacilli resembling Neisseria, Haemophilus, or Moraxella
Epidemiology
| Feature | Detail |
|---|---|
| Natural habitat | Soil, water, fruits/vegetables; can colonize human skin and oropharynx |
| Desiccation survival | Weeks on dry surfaces — highly unusual for gram-negative rods; enables persistent hospital contamination |
| US burden (CDC estimate) | ~12,000 infections/year; 7,300 MDR; ~500 deaths |
| Clonal lineages | Three international clonal lineages (ICL); ICL I and ICL II are multidrug resistant |
| Climate | Historically hot/humid climates; now worldwide — including temperate regions |
| Seasonality | Infections peak in late summer |
| COVID-19 impact | Pandemic significantly worsened carbapenem-resistant A. baumannii (CRAB) spread |
Pathogenesis & Resistance Mechanisms
A. baumannii has a small core genome and large accessory/dispensable genome — conferring remarkable genomic plasticity:
- Acquires exogenous resistance genes via horizontal gene transfer (from alien genomic islands flanked by integrases, transposases, insertion sequences)
- Intrinsic β-lactamases destroy 1st/2nd-generation cephalosporins
- Extended-spectrum β-lactamases (ESBLs) → resistance to 3rd/4th-gen cephalosporins
- OXA-family carbapenemases (class D β-lactamases, including OXA-23, OXA-24, OXA-58) → carbapenem resistance
- Acinetobacter-derived cephalosporinases (ADC) — intrinsic
- Efflux pumps, porin loss, and PBP modifications contribute additional resistance
Risk Factors for Infection
- Prolonged ICU stay
- Mechanical ventilation / tracheostomy
- Central venous catheterization
- Enteral feedings
- Prior antibiotics: 3rd-gen cephalosporins, fluoroquinolones, carbapenems (CRAB acquisition especially linked to prior carbapenem use)
- Nursing home residence, burns, major surgery
- Community-acquired risk: alcoholism, smoking, COPD, diabetes, malignancy (Southeast Asia predominantly)
Clinical Syndromes
| Syndrome | Notes |
|---|---|
| VAP/HAP | Most common; ICU setting; often MDR strains |
| Bloodstream infection | Frequently nosocomial; associated with high mortality |
| Wound/burn infections | Especially in combat-related trauma or burn units |
| Community-acquired pneumonia | Hot/humid climates, SE Asia; in US — male alcoholics. Presents with shock, ARDS, DIC; mortality >50%; bacteremia common |
| UTI | Catheter-associated |
| Meningitis | Post-neurosurgical; rare |
Treatment
Carbapenem-Susceptible A. baumannii
- First choice: Ampicillin-sulbactam (sulbactam component has intrinsic activity via PBP2/PBP3 binding)
- Alternatives: Cefepime, meropenem, imipenem (based on susceptibility)
- Community isolates may also respond to fluoroquinolones, TMP-SMX
Carbapenem-Resistant A. baumannii (CRAB)
Based on 2024 IDSA Guidance on Treatment of Antimicrobial-Resistant Gram-Negative Infections:
| Regimen | Details |
|---|---|
| Preferred | Sulbactam-durlobactam 1g/1g q6h (infuse over 3h) + carbapenem |
| Alternative | High-dose ampicillin-sulbactam (9g q8h over 4h or 27g/day continuous infusion) + polymyxin B, minocycline, tigecycline, or cefiderocol |
Key drug details:
- Sulbactam-durlobactam (FDA-approved 2023): Durlobactam is a novel diazabicyclooctane (non-β-lactam) β-lactamase inhibitor that protects sulbactam against ADC and OXA carbapenemases. In an RCT of 125 CRAB patients, 28-day mortality 19% vs 32% for colistin (both with imipenem-cilastatin).
- High-dose ampicillin-sulbactam rationale: higher doses optimize sulbactam binding to PBP2 and PBP3; based on meta-analyses of observational data.
- Cefiderocol (2g q8h over 3h): siderophore cephalosporin; use in combination, not monotherapy.
- Colistin/polymyxin B: last-resort agents; in vitro tests may miss heteroresistance (resistant subpopulations) — use with caution.
- Minocycline: 200mg loading, then 100mg q12h.
- Tigecycline: high-dose regimens preferred; limited PK for bacteremia.
Therapeutic dosing table (Harrison's 22E, p. 1340):
| Antibiotic | Dose |
|---|---|
| Sulbactam-durlobactam | 1g/1g q6h over 3h |
| Ampicillin-sulbactam | 3g q4h / 9g q8h over 4h / 27g/24h continuous |
| Meropenem | 2g q8h over 3h |
| Imipenem-cilastatin | 500mg q6h over 3h |
| Cefiderocol | 2g q8h over 3h |
| Colistin | 5mg CBA/kg loading → 2.5 mg CBA × (1.5 × CrCl + 30) mg/day |
⚠️ Polymyxin-meropenem and polymyxin-rifampin combinations are discouraged by IDSA 2024 guidelines.
Infection Control
Because A. baumannii survives desiccation for weeks on inanimate surfaces, environmental decontamination is critical:
- Contact precautions
- Rigorous hand hygiene
- Terminal cleaning of ICU rooms and equipment (ventilators, catheters)
- Antibiotic stewardship to reduce selective pressure
Recent Evidence (2023–2025)
- [PMID 40787933] (Clin Microbiol Rev, 2025): Comprehensive review of drug-resistant A. baumannii mortality, emerging treatments (cefiderocol, sulbactam-durlobactam, phage therapy), and future pharmacological targets — WHO priority pathogen.
- [PMID 40216090] (Int J Antimicrob Agents, 2025): Bayesian meta-analysis on phage therapy against MDR A. baumannii — emerging alternative/adjunct.
- [PMID 37666449] (Clin Microbiol Infect, 2024): Global meta-analysis of cefiderocol non-susceptibility across A. baumannii and other Gram-negatives — cefiderocol resistance is emerging.
Sources: Harrison's Principles of Internal Medicine, 22nd Ed. (2025), pp. 1338–1341 · Murray & Nadel's Textbook of Respiratory Medicine · Medical Microbiology 9e · 2024 IDSA Guidance on AMR Gram-Negative Infections
What is clinical features
Reading File
Reading File
I now have what I need. Here is the full clinical features section:
Clinical Features of Acinetobacter baumannii
A. baumannii causes distinct clinical syndromes depending on the setting (healthcare-associated, community-acquired, or war/disaster zone). It is primarily an opportunistic pathogen — it rarely causes disease in immunocompetent hosts.
1. Ventilator-Associated Pneumonia (VAP) / Hospital-Acquired Pneumonia (HAP)
The most common clinical syndrome caused by A. baumannii.
- Occurs in ICU patients on mechanical ventilation
- Presents with: fever, purulent tracheal secretions, new or progressive infiltrates on CXR, worsening oxygenation
- Gram stain of tracheal aspirate shows plump, paired gram-negative coccobacilli
- Key challenge: Distinguishing true infection from colonization — A. baumannii frequently colonizes the respiratory tract of ICU patients without causing disease
- Most isolates in this setting are multidrug-resistant (MDR) or extensively drug-resistant (XDR)
2. Bloodstream Infection (Bacteremia)
- Usually catheter-related or secondary to pneumonia/wound infection
- Presents with: high fever (or hypothermia), rigors, hemodynamic instability
- Septic shock is common, especially with MDR strains
- Mortality is high, particularly with carbapenem-resistant isolates
3. Community-Acquired Pneumonia (CAP)
A severe, distinct presentation seen in tropical/subtropical climates (SE Asia, northern Australia) and rarely in temperate zones:
| Feature | Detail |
|---|---|
| Onset | Acute, fulminant |
| Symptoms | High fever, productive cough (purulent sputum), dyspnea |
| Complications | Septic shock, ARDS, DIC — all three may occur together |
| Labs | Leukopenia, thrombocytopenia |
| Imaging | ARDS pattern or pleural effusions |
| Bacteremia | Common |
| Mortality | >50% |
| Highest risk for death | Leukopenia, septic shock, or respiratory failure |
| Risk factors | Alcohol abuse, diabetes, COPD, smoking, malignancy |
4. Wound & Soft Tissue Infections
- Particularly seen in war-zone casualties (Iraq, Afghanistan veterans) and disaster victims (tsunamis, earthquakes, terrorist attacks)
- Typically acquired from contaminated hospital/field-hospital environment, not the patient's skin flora
- Presents as: infected traumatic wounds, cellulitis, necrotizing soft tissue infection
- Often polymicrobial
- Genetic fingerprinting of isolates matches inanimate surfaces in field hospitals
5. Urinary Tract Infection (UTI)
- Almost exclusively catheter-associated
- May be asymptomatic bacteriuria or symptomatic cystitis/pyelonephritis
- Often a source of bacteremia in ICU patients
6. Meningitis
- Post-neurosurgical setting (craniotomy, external ventricular drain, CSF shunt)
- Presents with: fever, neck stiffness, altered consciousness, CSF pleocytosis
- Rare but carries high mortality
Key Clinical Distinctions
| Feature | HAP/VAP | Community-acquired |
|---|---|---|
| Setting | ICU, mechanically ventilated | Tropical regions, outpatients |
| Resistance | Typically MDR/XDR | Usually susceptible |
| Severity | Variable | Fulminant — shock, ARDS, DIC |
| Mortality | Variable | >50% |
| Bacteremia | Less common | Common |
| Host | Critically ill, immunocompromised | Previously healthy or comorbidities |
Colonization vs. Infection — A Critical Clinical Problem
A. baumannii frequently colonizes the respiratory tract, wounds, and skin of ICU patients without causing true infection. Distinguishing colonization from infection requires:
- Clinical signs of infection (fever, leukocytosis, hemodynamic changes)
- Radiographic progression
- Purulent secretions with heavy growth on culture
- Absence of alternative explanation
Treatment of colonization alone is not recommended and drives resistance.
Source: Harrison's Principles of Internal Medicine, 22nd Ed. (2025), Ch. 167, pp. 1338–1341 · Murray & Nadel's Textbook of Respiratory Medicine
This is a shared conversation. Sign in to Orris to start your own chat.